Clinical Trial Update: Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

Phase 2 trial update on Centanafadine sustained-release for adults with ADHD completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Centanafadine sustained-release (CTN SR) (centanafadine)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 2 | Status: COMPLETED | Results posted: 2021-11-11